This book provides an update on heterocyclic compounds that serve as key components of anti-cancer agents administered in pre-clinical settings. Many of the compounds highlighted in the book are being actively investigated for the bioactive properties against a range of cancer cell lines. There is potential for heterocyclic compounds to design agents that can target specific molecules to treat different types of cancers. Chapters are contributed by experts in pharmaceutical chemistry and are written to give a general overview of the topic to readers involved in all levels of research and decision-making in pharmaceutical chemistry and anti-cancer drug design. Part II of the book set covers these topics: - Anticancer targets for heterocyclic lead compounds - Coumarin hybrids for cancer treatments - Progress in nitrogen and sulphur-based heterocyclic compounds for their anticancer activity - Imidazole as an anticancer heterocyclic ring - Morpholine for profiling anticancer lead compounds - Natural products as anticancer agents

Obesity is a complex health problem, caused by a number of factors such as excessive food intake, lack of physical activity, genetic predisposition, endocrine disorders, medications and psychiatric illnesses. Onset of obesity in both the developing and the developed world has reached epidemic proportions. In response to this, efforts to control and treat obesity have also been vigorously pursued, ranging from raising awareness about lifestyle changes to the discovery and development of safe and effective anti-obesity drugs. Anti-obesity Drug Discovery and Development is focused on this very important area of healthcare research. Fifteen well written reviews make this special volume an excellent compilation of recent developments in anti-obesity treatment. The reviews cover a variety of topics including the development of specific, safe and effective receptor antagonists, the role of epithelial endocrine cells and post operative treatment strategies. This book should be useful to clinicians and medicinal chemists involved in ant-obesity research and therapy.

Obesity is a complex health problem, caused by a number of factors such as excessive food intake, lack of physical activity, genetic predisposition, endocrine disorders, medications and psychiatric illnesses. Onset of obesity in both the developing and the developed world has reached epidemic proportions. In response to this, efforts to control and treat obesity have also been vigorously pursued, ranging from raising awareness about lifestyle changes to the discovery and development of safe and effective anti-obesity drugs. Anti-obesity Drug Discovery and Development is focused on this very important area of healthcare research. Fifteen well written reviews make this special volume an excellent compilation of recent developments in anti-obesity treatment. The reviews cover a variety of topics including the development of specific, safe and effective receptor antagonists, the role of epithelial endocrine cells and post operative treatment strategies. This book should be useful to clinicians and medicinal chemists involved in ant-obesity research and therapy.

Obesity is a complex health problem, caused by a number of factors such as excessive food intake, lack of physical activity, genetic predisposition, endocrine disorders, medications and psychiatric illnesses. Onset of obesity in both the developing and the developed world has reached epidemic proportions. In response to this, efforts to control and treat obesity have also been vigorously pursued, ranging from raising awareness about lifestyle changes to the discovery and development of safe and effective anti-obesity drugs. Anti-obesity Drug Discovery and Development is focused on this very important area of healthcare research. The third volume of this series is dedicated to anti-obesity treatments including updates on new therapeutics for obesity, Nesfatin-1 and its therapeutic uses, the role of proteomics in pediatric anti-obesity treatment, the role of oxidative stress in childhood obesity and a review of data on gut microbiota as a treatment option for obesity.

Obesity is a complex health problem, caused by a number of factors such as excessive food intake, lack of physical activity, genetic predisposition, endocrine disorders, medications and psychiatric illnesses. The incidence of obesity among populations in both the developing and the developed world has reached epidemic proportions. In response to this, efforts to control and treat obesity have also been vigorously pursued, ranging from activities focused on raising awareness about lifestyle changes to the discovery and development of safe and effective anti-obesity drugs. Anti-obesity Drug Discovery and Development is a book series focused on this very important area of healthcare research. Each volume presents insightful updates on pharmaceutical research and development for clinical researchers and healthcare professionals involved in obesity treatment programs.</p> <p> The fourth volume of this series covers 6 reviews on anti-obesity treatment strategies including updates on obesity and cancer prevention through dietary modulation, the role of anti-obesity medications in polycystic ovary syndrome, potential anti-obesity strategies targeting mitochondria, calcium silicate based formulations for anti-obesity therapy, and the identification of obesity medications from natural products and plants.</p>

Obesity is a complex health problem, caused by a number of factors such as excessive food intake, lack of physical activity, genetic predisposition, endocrine disorders, medications and psychiatric illnesses. The incidence of obesity among populations in both the developing and the developed world has reached epidemic proportions. In response to this, efforts to control and treat obesity have also been vigorously pursued, ranging from activities focused on raising awareness about lifestyle changes to the discovery and development of safe and effective anti-obesity drugs. Anti-obesity Drug Discovery and Development is a book series focused on this very important area of healthcare research. Each volume presents insightful updates on pharmaceutical research and development for clinical researchers and healthcare professionals involved in obesity treatment programs. The fifth volume of this series is a compilation of 6 reviews of interesting topics on the subject that highlight different aspects of obesity treatment and management, some of which are novel approaches. Topics covered in this volume include: - the effect of sleep on weight and obesity management - AMPK as a postulated target for metabolic syndrome and obesity - Harnessing addiction neuroscience to treat obesity - Current treatment of obesity versus the next generation of anti-obesogenic drugs: an ecologically and sustainable approach to health - Leptin and leptin sensitizers for the treatment of obesity related conditions - MicroRNAs as targets for the management of obesity

Animal models of diseases play a pivotal role in drug discovery and development, not only for proof of the concept studies of efficacy, PK/PD relationship but also for drug safety assessment. Since considerable differences in variables exist between animal models and human models (such as genetics, physiology, anatomy, gene expression, heterogeneity of disease conditions, etc.), not all the preclinical models are able to represent the pathophysiological conditions in human diseases. Therefore, partly due to the lack of congruency between animal and human disease models, several proposed therapeutic agents in the past decades have been demonstrated to be effective in preclinical models but failed in clinical studies. This e-book focuses on animal models of diseases from a translational perspective and highlights the key advantages and limitations of each model described to facilitate drug discovery and development. A unique feature of the volume is that it contains a selection of details disease models in various therapeutic niches with significant unmet medical needs, including inflammation, neurological diseases, cardiovascular and metabolic diseases, and oncology. This e-book is, therefore, of considerable value to researchers and clinicians involved in drug discovery and development as well as pathology.